Work

A phase II trial of an oral CDK 4/6 inhibitor, PD0332991, in advanced breast cancer.

Year: 2013

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2013.31.15_suppl.519

Authors: Angela DeMichele, Amy Sanders Clark, Daniel Heitjan, Sophia Randolph, Maryann Gallagher, Priti Lal, Michael D Feldman, Paul J. Zhang, Allison Schnader, Kelly Zafman, Susan M. Domchek, Keerthi Gogineni, Stephen Michael Keefe, Kevin R. Fox, Peter J. O'Dwyer

Institutions: Abramson Cancer Center, University of Pennsylvania, Hospital of the University of Pennsylvania, Pfizer (United States), University of Pennsylvania Health System

Language: English

Topic: Advanced Breast Cancer Therapies

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2600318786

Cites:

Cited by: 20

Related to: 10